HBC Hofseth Biocare

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC") holds 1,500,000 shares personally and has held 1,747,976 shares indirectly through the Bonafide fund. Redemption of the fund has led to transfer of his indirect holdings to his personal account, and hence Mr. Baldegger now personally holds 3,247,976 shares and zero indirect ownership in HBC, equal to approximately 0.82 % of the total outstanding A-shares with voting rights.

For further information, contact:

Jon Olav Ødegård, CEO of Hofseth BioCare ASA

Phone:

E-mail:

This information is subject to the disclosure requirements in the Market Abuse Regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.



EN
20/02/2025

Underlying

HBCHofseth Biocare

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: CONTEMPLATING UNSECURED BOND ISSUANCE

Hofseth Biocare ASA: CONTEMPLATING UNSECURED BOND ISSUANCE Hofseth BioCare ASA has retained Novum Asset Management AG to investigate the potential issuance of CHF-denominated unsecured bonds with an expected volume of up to CHF 8 million, towards investors in Switzerland and Liechtenstein. Further, the Company may contact investors in Norway directly. The Company targets a tenor of three years for the Bonds. Further information about any issuance of Bonds, and the terms and conditions of such bonds, will be given in due course. For further information, please contact:Jon Olav Ødegård, CE...

7h / 11m 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: HBC ACCELERATES IN HUMAN HEALTH AND PET NUTRITION...

Hofseth Biocare ASA: HBC ACCELERATES IN HUMAN HEALTH AND PET NUTRITION THROUGH A STRATEGIC PARTNERSHIP WITH SYMRISE TO BUILD OUT BERKÅK, TRIPLING THE MANUFACTURING CAPACITY OF THE GROUP HBC will accelerate its manufacturing scale and market reach with the construction of a second enzymatic hydrolysis plant in Berkåk, Norway. Symrise will support the financing of the project through a EUR 5m loan. The partnership ideally complements both HBC and Symrise’s current portfolio with science-led, clinically proven marine ingredients for Consumer Health. HBC have also signed an exclusive distributi...

February 21, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC") holds 1,500,000 shares personally and has held 1,747,976 shares indirectly through the Bonafide fund. Redemption of the fund has led to transfer of his indirect holdings to his personal account, and hence Mr. Baldegger now personally holds 3,247,976 shares and zero indirect ownership in HBC, equal to approximately 0.82 % of the total outstanding A-shares with voting rights. For further information, contact:Jon Olav Ødegård, CEO of Hofset...

February 20, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: FOURTH QUARTER & FULL YEAR 2024 FINANCIAL REPORT

Hofseth Biocare ASA: FOURTH QUARTER & FULL YEAR 2024 FINANCIAL REPORT HBC achieved full-year sales revenue of NOK 256.8 million, a 35% increase from 2023, with strong momentum in higher-margin B2B human nutrition. The shift towards premium products, particularly CalGo® and OmeGo®, contributed to the revenue boost, while gross margins improved across all segments. The company’s restructuring efforts in Q4 led to improved scalability, with cost optimization initiatives streamlining operations. Organization re-structuring during the fourth quarter, resulted in one-time cost effects of 1.9m, r...

February 14, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC") has today purchased 700,000 shares in HBC at an average price of NOK 1.202837 per share. As a result of the transaction, Mr. Baldegger holds 1,500,000 shares personally and 1,747,853 shares indirectly through the Bonafide fund, in HBC equal to approximately 0.82 % of the total outstanding A-shares with voting rights. Please see the attached notification form for further information. Contact: Jon Olav Ødegård, CEO of Hofseth BioCare ...

December 12, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch